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Abstract
Background: Genome-wide association studies have reported that the 9p21.3 locus confers risk for coronary artery
disease (CAD). However, it is not known whether rs10811656 is linked with CAD in a Chinese population. Thus,
the purpose of this study was to investigate the potential association between rs10811656 and the risk of CAD in
a Chinese population.
Methods: We conducted a hospital-based, case–control study with 251 CAD patients and 304 controls to examine
the potential association of rs10811656 with CAD.
Results: The frequencies of the TT genotypes in CAD cases were significantly different from those in controls
(adjusted OR: 1.96, 95 % CI: 1.09–3.505, P = 0.024). Compared to controls, rs10811656 was significantly associated
with the stable angina pectoris (adjusted OR: 1.42, 95 % CI: 1.06–1.90, P = 0.017), but not with acute coronary
syndrome. There was also a highly significant association of rs10811656 with double-vessel and triple-vessel disease
when patients were divided into subgroups based on the number of diseased vessels (adjusted OR: 1.68 and 1.60,
95 % CI: 1.14–2.44 and 1.10–2.33, P = 0.009 and 0.02, respectively).
Conclusion: Our results suggest that the rs10811656 locus might be associated with CAD in a Chinese Han
population.
Keywords: SNP, single nucleotide polymorphism, Association, rs10811656, CAD, coronary artery disease,
Susceptibility
Background
Coronary artery disease (CAD) is one of the major
causes of morbidity and mortality throughout the
world, including China [1, 2]. Epidemiological studies
have identified several risk factors for CAD, including
dyslipidaemia, diabetes, obesity, smoking and genetic
variance [1]. Most recently, genomics analyses have
revealed a series of new candidate markers that may
contribute to the pathogenesis of CAD [3].
The 9p21.3 risk locus spans a >50-kb genomic region
and comprises 59 linked single nucleotide polymor-
phisms (SNPs) that are in strong linkage disequilibrium.
This genomic region encodes the cyclin-dependent kin-
ase inhibitors, CDKN2A (p16 and p14) and CDKN2B
(p15) [4]. Recently, genome-wide association studies
have shown that common variants in the 9p21.3 gene
desert might be robustly associated with the risk of
CAD, acute coronary syndrome (ACS), early atheroscler-
osis, abdominal aortic aneurysm, and intracranial
aneurysm [5–7], although the mechanisms underlying
these associations are not completely understood.
However, it remains unknown whether rs10811656
polymorphism in this region might be linked with the
risk of CAD.
The objective of the present hospital-based, case–con-
trol study was to investigate the potential association
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between rs10811656 and the risk of CAD, and further
replicate the positive association of rs10811656 and ACS
in a Chinese population.
Methods
Study population
This association study consecutively enrolled 251 unre-
lated consecutive CAD patients, who were all admitted
to Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital, East Campus from January 2014 to
December 2015. CAD was defined as ≥ 50 % luminal
narrowing in at least one coronary artery. Patients with
CAD were divided into subgroups with 1-vessel, 2-vessel
or 3-vessel disease according to the number of signifi-
cantly affected vessels using the Coronary Artery Surgery
Study classification [8]. Two cardiologists who were
blinded to all patient information assessed the angio-
grams. Control subjects (n = 304), who underwent
coronary angiography to rule out CAD, were also en-
rolled during the same time period at the same hos-
pital. All subjects enrolled in this study were of Han
Chinese origin and had no history of significant con-
comitant diseases, including cardiomyopathy, bleeding
disorders, renal failure, thyroid disease, pulmonary
hypertension, and malignancy. This study was ap-
proved by the Ethics Committee of Shanghai Jiao
Tong University Affiliated Sixth People’s Hospital,
East Campus and informed consent was obtained
from each participant. All authors had no access to
information that could identify individual participants
after data collection.
DNA extraction and genotyping
Peripheral venous blood was drawn from each partici-
pant in the first day after admission. Genomic DNA was
extracted using the AxyPrep DNA Blood kit (Axygen
Scientific Inc, Union City, CA, USA). The rs10811656
polymorphism was genotyped by PCR-LDR sequencing
method, as reported previously [9].
Statistical analysis
The allele frequencies and genotype distributions of the
CAD cases and controls were compared using chi-
square (χ2) tests. Among the controls, the genotype
frequencies were tested using the χ2-test test for the
Hardy-Weinberg equilibrium (HWE). The association
between the genotypes and CAD was evaluated by com-
puting odds ratios (ORs) and 95 % confidence intervals
(95 % CIs). A multiple logistic regression model was
used to adjust for covariates including age, sex, body
mass index, smoking status, hypertension, diabetes, and
dyslipidemia. The linear trend in the association of
rs10811656 polymorphism with CAD severity was evalu-
ated by the χ2-test for trend. Two-tailed P values < 0.05
were considered significant. All of the statistical analyses
were performed using SPSS for Windows version 13.0
(SPSS, Inc., Chicago, USA).
Results
Demographic information
The baseline characteristics of the case and control sub-
jects are presented in Table 1. Patients with CAD were
older and had higher rate of smoked and diabetes com-
pared to the control subjects. Based on coronary angiog-
raphy, 133 (43.75 %) patients in the CAD group had
single-vessel disease, 85 (27.97 %) had double-vessel
disease and 86 (28.28 %) had triple-vessel disease.
Genotypes and allele frequencies in CAD cases and
controls and their associations with CAD
The minor allele (T) frequency of rs10811656 was
0.3817, and the genotype distribution in our study sub-
jects showed no deviation from the Hardy–Weinberg
equilibrium (P > 0.05). The distribution of the T geno-
type was also markedly different between CAD patients
and controls (P = 0.024), as shown in Table 2. After
adjustment for age, sex, hypertension, diabetes, and dys-
lipidemia, the OR for CAD in subjects with the variant
genotypes (CT and TT) was 1.43 (95 % CI: 0.98–2.08, P
= 0.057). We also found that homozygous TT carriers
had a 96 % increase in risk of CAD compared with CC
carriers (95 % CI: 1.09–3.505, P = 0.024). In the sub-
group of patients with stable angina pectoris (SAP),
carriers of TT homozygous carriers had a 42 % increase
in the risk of CAD compared with the CC carriers (95 %
CI: 1.06–1.90, P = 0.017). However, no significant associ-
ation was observed with ACS (Table 3.).
Table 1 Baseline characteristics of the study subjects
Characteristic Controls (n = 251) CAD cases (n = 304) P values
Age (years) 63.0 ± 14.5 67.13 ± 11.7 <0.001
Sex (male), n (%) 47 (39.8) 127 (63.8) <0.001
Hypertension, n (%) 73 (61.9) 141 (71.2) 0.086
Diabetes, n (%) 16 (13.6) 65 (32.7) <0.001
Dyslipidemia, n (%) 39 (33.1) 76 (38.2) 0.358
Smoking, n (%) 23 (19.5) 71 (35.7) 0.002
TC (mmol/L) 4.57 ± 1.70 4.41 ± 1.26 0.21
TG (mmol/L) 1.94 ± 5.35 1.69 ± 2.02 0.45
HDL-C (mmol/L) 1.18 ± 0.30 1.15 ± 0.27 0.23
LDL-C (mmol/L) 2.81 ± 076 2.69 ± 0.86 0.09
Number of diseased vessels
One, n (%) - 133 (43.75 %) —
Two, n (%) - 85 (27.97 %) —
Three n (%) - 86 (28.28 %) —
HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein
cholesterol, TC total cholesterol, TG triglyceride
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Stratified analyses of the polymorphism and CAD
Stratified analyses were conducted according to age,
gender, and smoking status (Table 4). We noted that T
allele was significantly associated with CAD in males
(adjusted OR: 1.82, 95 % CI: 1.10–3.01, P = 0.02) and
smokers (adjusted OR: 2.13, 95 % CI: 1.06–4.26, P =
0.033), but not in females (adjusted OR: 1.09, 95 % CI:
0.62–1.91, P =NS) or non-smokers (adjusted OR: 1.21,
95 % CI: 0.77–1.89, P =NS). Patients with CAD were
subclassified into 3 subgroups (single-, double- and
triple-vessel disease) based on the number of stenotic
coronary arteries. The frequency of patients with T vari-
ant genotypes increased from double- to triple-vessel
disease, but not with single-vessel disease (Table 5).
Lipid profiles of CAD cases and controls in the
rs10811656 genotypes
Table 6 shows lipid profiles according to the rs10811656
genotypes in the CAD and control groups. We did not
find a significant association between the rs10811656
genotypes and serum triglycerides, HDL-C or LDL-C
levels in these two groups.
Discussion
The present case–control study demonstrated that the
homozygous TT genotype of rs10811656 on chromo-
some 9p21.3 increased the risk of CAD in a Chinese
population. The 9p21.3 risk locus of the genes encoding
the cyclin-dependent kinase inhibitors, CDKN2A (p16
and p14) and CDKN2B (p15), are known as suppressors
that control cell cycle and cellular senescence [10, 11].
Moreover, smooth muscle cells homozygous for the
9p21.3 risk alleles showed reduced expression of p16
and p15, thus increasing proliferation and causing failure
to enter senescence in several studies [4, 10]. In addition,
homozygous carriers of the 9p21 risk allele exhibit
upregulation of gene sets involved in cellular prolifera-
tion of white blood cells [12].
Harismendy et al. demonstrated that the 9p21.3 locus
alters CAD risk by modulating inflammatory signaling
through altered STAT1 binding and may modify immune
responses by regulating expression of IFN, a 21 or related
type I IFN; and this in turn affects the expression of the
cyclin-dependent kinase inhibitor gene, CDKN2A/B,
which is important regulator of cell proliferation, aging,
and apoptosis [13]. Furthermore, in the primary
HAoSMCs homozygous TT genotype of rs10811656,
reduced expression of p16 and p15disrups TEAD factor
binding and TEAD3-dependent transforming growth fac-
tor β induction of p16, indicating the TT genotype of
rs10811656 could be a functional variant [14].
In the present study, we observed that the distribution
of T genotype was also markedly different between CAD
patients and controls After adjusting for risk factors in-
cluding age, sex, smoking status, hypertension, diabetes,
and dyslipidemia, the OR for CAD in subjects with the
variant genotypes (CT and TT) was 1.43, which was of
borderline significance (P = 0.057). We also found that
homozygous TT carriers had a 96 % increase in the risk
of CAD compared with the CC carriers (P = 0.024). In
addition, TT genotype carriers had a 42 % increased risk
of SAP (95 % CI: 1.06–1.90, P = 0.017); however, the risk
of ACS was not significantly increased. Our results are
not consistent with the observations of Qiang et al. [15].
They reported that there was a higher risk of ACS in
subjects with than without the rs10811656 T allele [15].
Table 2 Distribution of genotypes and the CAD risk estimates for rs10811656
Controls (n = 243) Cases (n = 298) Crude OR (95 % CI) P Adjusteda OR (95 % CI) P
Genotypes, n (%)
rs10811656 CC 99 (40.7) 103 (34.6) 1.00 1.00
CT 118 (48.6) 147 (49.3) 1.19 (0.83–1.72) 0.33 1.32 (0.89–1.94) 0.164
TT 26 (10.7) 48 (16.1) 1.77 (1.02–3.08)) 0.041 1.96 (1.09–3.505) 0.024
CT + TT 144 (59.3) 195 (65.4) 1.30 (0.92–1.84) 0.14 1.43 (0.98–2.08) 0.057
CI confidence interval, OR odds ratio
aAdjusted for age, sex, body mass index, smoking status, hypertension, diabetes, dyslipidemia
Table 3 Association of rs10811656 with SAP and ACS
SNP Groups Genotype Crude OR (95 % CI) P Adjusted OR (95 % CI)a P
rs10811656 CC/CT/TT
Control 99/118/26 1 1
SAP 66/99/36 1.36 (1.02–1.79) 0.03 1.42 (1.06–1.90) 0.017
ACS 34/48/12 1.16 (0.81–1.65) 0.41 1.27 (0.87–1.85) 0.21
ACS acute coronary syndrome, CI confidence interval, OR odds ratio, SAP stable angina pectoris
aAdjusted for age, sex, body mass index, smoking status, hypertension, diabetes, and dyslipidemia
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Studies examining the association of disease severity
with the 9p21 genotype are conflicting [15, 16]. Ander-
son et al. and Chen et al. found that the 9p21.3 allele
predicted the prevelance of CAD, but it did not predict
its severity [16, 17]. The investigation by Muendlein
et al. showed that the variant rs1333049 was associated
with angiographically characterized coronary athero-
sclerosis instead of plaque instability, rupture, and
thrombogenesis [18]. However, in a study of 769
patients, Ye et al. demonstrated that 9p21 is associated
with a higher prevalence and 5-year progression of pre-
clinical atherosclerosis in the carotid vessels, suggesting
that 9p21 promotes plaque formation [19]. Although we
did not observe a significant relationship between the
rs10811656 T allele and ACS, we found that the fre-
quency of patients with T-variant genotypes increased
from double- to triple-vessel disease, whereas there was
no association with single-vessel disease. Buysschaert
et al. demonstrated that certain alleles on the 9p21 locus
are associated with a predisposition to recurrent myocar-
dial infarction and cardiac death within 6 months after
the primary event [20].
Associations of SNPs on chromosome 9p21.3 with
cardiovascular disease may reflect an influence on the
development and progression of coronary atherosclerosis
in native arteries rather than causing acute rupture of
vulnerable plaques and thrombosis. Cheng et al. found
that rs10811661 on 9p21.3, as the neighbor SNP of
rs10811656, was associated with type 2 diabetes and
CAD, but it was not correlated with the severity of cor-
onary atherosclerosis in a Chinese Han population [21].
The results of these previous studies taken together with
our results suggest that further investigation is war-
ranted to determine whether the CAD risk alleles on
9p21.3 are related to the severity of coronary
atherosclerosis.
Our stratification analysis showed that the T allele
was significantly associated with CAD in males. Males
who carried the variant genotypes (TT + TC) had a
significantly higher risk of CAD than the CC carriers.
The T allele could be a genetic susceptibility marker
for CAD in males. Valentina et al., reported that in
males with breast cancer, the rs1011970/9p21.3 risk
genotype was associated with HER2+ disease [22]. Lin
et al. reported that chromosome 9p21 had a significant
association with carotid atherosclerosis, especially the
intima-media thickness of the internal carotid artery, in a
gender-specific manner in a Chinese Han population [23].
However, little is known regarding the functional conse-
quences of variants on 9p21.3, or why the variants exert a
Table 4 Stratification analysis by age, sex and smoking statue for the association of rs10811656 with CAD




rs10811656 CC/CT + TT
Age (median)
< 66 years 43/88 47/88 1.09 (0.66–1.82) 0.73 1.20 (0.69–2.10) 0.521
≥ 66 years 60/107 52/56 1.66 (1.01–2.71) 0.045 1.63 (0.98–2.72) 0.061
Sex
Males 63/128 50/61 1.66 (1.03–2.69) 0.037 1.82 (1.10–3.01) 0.02
Females 49/83 40/67 0.98 (0.58–1.67) 0.967 1.09 (0.62–1.91) 0.76
Smoking
Yes 37/72 27/30 1.75 (0.91–3.37) 0.093 2.13 (1.06–4.26) 0.033
No 66/123 72/114 1.17 (0.77–1.79) 0.447 1.21 (0.77–1.89) 0.398
MAF rs10811656 T = 38.17 %, P for HW = 0.379793
CI confidence interval, OR odds ratio
aAdjusted for age, sex, body mass index, smoking status, hypertension, diabetes and dyslipidemia
Table 5 Association of rs10811656 with the number of diseased vessels
SNP Group Genotype Crude OR (95 % CI) P Adjusted OR (95 % CI)a P
rs10811656 CC/CT/TT
Control 99/118/26 1 1
One-vessel disease 49/67/14 1.07 (0.78–1.48) 0.67 1.14 (0.82–1.60) 0.42
Two-vessel disease 25/43/17 1.57 (1.09–227) 0.015 1.68 (1.14–2.44) 0.009
Three-vessel disease 29/37/17 1.41 (0.97–2.04) 0.068 1.60 (1.10–2.33) 0.02
CI confidence interval, OR odds ratio
aAdjusted for age, sex, body mass index, smoking status, hypertension, diabetes, and dyslipidemia
Yan et al. Lipids in Health and Disease  (2016) 15:126 Page 4 of 6
gender-specific effect on the risk of CAD. Further research
will be needed to elucidate the biological significance of
these associations.
We noted that among smokers, carriers of homozy-
gous TT and heterozygous TC had an increased risk of
CAD than CC genotype carriers. Our result suggests
that the rs10811656 polymorphism may be factor that
contributes to smoking-related CAD in a Chinese popu-
lation. There was also no significant association between
the rs10811656 genotypes and serum triglycerides,
HDL-C and LDL-C levels in the CAD patients and con-
trols. Therefore, our study revealed that the risk allele
was associated with angiographically characterized
coronary atherosclerosis, suggesting that the risk SNP
exerts cell or tissue-specific effects relevant to athero-
sclerosis rather than affecting the traditional risk factors
for CAD.
Our study has several limitations. First, selection
bias and a relatively small sample size in the present
study may have reduced the statistical power of the
results, even though the genotype distribution of
patients and controls in our study was compatible
with the Hardy–Weinberg expectations. Secondly, a
prospective long-term outcome study is warranted to
analyze the association of polymorphism with long-
term prognosis in CAD patients. Lastly, our data
should be extrapolated to other regions and ethnic
groups cautiously.
Conclusion
To the best of our knowledge, the present study demon-
strates for the first time that the rs10811656 polymorph-
ism is associated with increased risk of CAD in a
Chinese population. Additionally, in male subjects and
smokers, rs10811656 homozygous carriers of TT have
an increased risk of CAD. Moreover, we found that the
rs10811656 T variant is significantly correlated with SAP
and angiographically characterized coronary disease
severity. In order to enhance understanding of the rela-
tionship between this polymorphism and risk of CAD,
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